Finasteride vs Spironolactone: What to Do When One Fails

This article has not yet completed qualified medical review. Treat it as a starting point for a conversation with a prescriber, not as individualized medical advice.

The direct answer

Finasteride and spironolactone are not interchangeable backups for each other. Finasteride lowers dihydrotestosterone (DHT) production by blocking the enzyme that makes it; spironolactone blocks the androgen receptor and modestly lowers circulating androgens by other routes. A patient who has adequately suppressed DHT on finasteride but still loses hair likely has a receptor-sensitivity problem that spironolactone is positioned to address. A patient whose DHT was never adequately suppressed has an adherence, metabolism, or dosing problem that switching drug class will not fix. Confirming which situation applies, with labs and a defined trial period, should come before either drug is declared a failure.

Know the two drugs before comparing them

Finasteride is a synthetic 4-azasteroid and selective inhibitor of the type II isoform of 5-alpha reductase, the enzyme that converts testosterone to DHT. It is FDA-approved as Propecia (1 mg/day) for male-pattern hair loss and as Proscar (5 mg/day) for benign prostatic hyperplasia. Use in women for female-pattern hair loss is off-label.

Spironolactone is a synthetic steroid that acts as a competitive aldosterone antagonist and, at the doses used off-label in dermatology, also competes with testosterone and DHT for binding at the androgen receptor while modestly suppressing gonadal and adrenal androgen production. It is FDA-approved as Aldactone for hypertension, edema, and primary hyperaldosteronism. Its use for acne or hair loss is off-label in every jurisdiction the FDA label covers.

Neither drug regenerates a follicle that has completely miniaturized, and both require ongoing daily use; stopping either one is followed by gradual loss of benefit, typically described in clinical practice as occurring over several months to a year, though the exact timeline has not been rigorously mapped in trials.

Why the reason for failure matters more than the drug label

A patient who fails finasteride because circulating free testosterone remains high despite falling DHT is a different case from a patient who fails because their follicles carry unusually dense androgen receptors. The first patient may respond to spironolactone's effect on androgen synthesis. The second may need a higher finasteride dose, addition of topical minoxidil, or referral rather than a class switch. Before labeling a drug as failed, checking free testosterone, DHEA-S, SHBG, and prolactin is reasonable clinical practice; a markedly elevated DHEA-S points toward adrenal androgen excess, which favors spironolactone or a combined oral contraceptive over a 5-alpha reductase inhibitor alone. This is standard endocrine reasoning applied to alopecia workups, not a claim drawn from a single trial, and a clinician should confirm the specific thresholds used at their lab.

When has finasteride actually failed?

Most dermatology practice treats a finasteride trial as inconclusive before roughly 12 months of consistent use at the correct dose, with progression documented by standardized photography or trichoscopy rather than subjective impression. Judging the drug at 3 or 6 months is generally considered premature because the hair cycle needs time to show a treatment effect.

Reasons hair loss may appear to continue despite finasteride:

• Inadequate DHT suppression. A minority of patients do not achieve the expected drop in DHT, whether from adherence gaps, drug interactions, or individual metabolism. Checking serum DHT partway through the trial is a reasonable audit before assuming the drug class has failed.
• Type I 5-alpha reductase predominance. Finasteride is selective for the type II isoenzyme. Some patients, including some women with polycystic ovarian syndrome, may have relatively more type I activity in skin and follicles. Dutasteride, which inhibits both isoforms, is sometimes considered in this situation, but it has its own longer half-life and side-effect profile and this substitution should be discussed with a prescriber rather than self-directed.
• A non-androgenic cause of hair loss. Telogen effluvium from iron deficiency or thyroid disease, trichotillomania, and scarring alopecias will not respond to any anti-androgen. If the clinical picture is atypical, a scalp biopsy or basic labs (ferritin, TSH, CBC) should be checked before attributing continued loss to drug failure.

In women using finasteride off-label, some clinicians use doses above the standard 1 mg/day, but the evidence for higher doses comes from small observational reports rather than controlled trials, and dose escalation should be a discussion with the prescriber, not a self-adjustment.

When has spironolactone actually failed?

For acne, most dermatology guidance treats a trial as adequate after roughly 3-6 months at a dose of at least 100 mg/day, since inflammatory lesion counts can continue to improve well past the first two months. For hair loss, response is judged over a similarly extended window and tends to be more variable and harder to predict than the acne response.

Reasons acne or hair loss may not improve on spironolactone:

• Subtherapeutic dosing. Many patients start at 25-50 mg/day and are never titrated upward because of side-effect concerns. In an otherwise healthy patient without kidney disease, higher doses within the labeled range can often be tolerated with monitoring, but titration decisions belong to the prescriber.
• A non-hormonal acne driver. Comedonal acne from follicular plugging, or a Gram-negative folliculitis that mimics acne, will not respond to androgen blockade and may need a different diagnosis and different treatment entirely.
• High adrenal androgen output. Spironolactone's effect on adrenal androgen production is modest. A patient with markedly elevated DHEA-S may need adjunctive treatment such as a combined oral contraceptive before the follicular response to spironolactone becomes visible.

Switching from finasteride to spironolactone

Switching makes clinical sense when DHT appears adequately suppressed but symptoms persist, when a patient is a woman already using hormonal contraception who wants to consolidate anti-androgen effects, or when finasteride's sexual or mood side effects are the reason for stopping and a receptor-level blocker is preferred instead.

There is no strong evidence that an abrupt switch causes a clinically meaningful rebound in hair loss, so stopping finasteride and starting spironolactone in the same week is a reasonable approach in principle, with dose titration guided by tolerance and lab monitoring. Spironolactone at doses used for acne or hair loss (generally above 50-100 mg/day) is not appropriate for men because of a high rate of gynecomastia and sexual side effects at those doses; low-dose spironolactone has occasionally been used as an adjunct in men who decline dutasteride, but this remains a niche, off-label practice that should be individualized by the prescriber.

Switching from spironolactone to finasteride

This direction of switch is relevant when a patient is planning pregnancy (both drugs should be stopped, since both carry a risk of feminizing a male fetus, and a washout period should be discussed with the prescriber before conception is attempted), when spironolactone's blood-pressure-lowering effect is causing symptomatic hypotension, or when a man trialing off-label spironolactone found the sexual side effects intolerable and finasteride's side-effect profile in men is more acceptable.

Evidence boundary: what is established, what is plausible, what is not

Established by FDA labeling and long clinical use: finasteride's mechanism (5-alpha reductase type II inhibition) and its approved indications for male-pattern hair loss and BPH; spironolactone's mechanism (aldosterone antagonism with androgen-receptor blockade) and its approved indications for hypertension, edema, and hyperaldosteronism; both drugs' contraindication in pregnancy due to feminization risk to a male fetus; spironolactone's need for renal function monitoring given its potassium-sparing effect.

Plausible but not established by controlled trials referenced here: that combining finasteride and spironolactone produces additive benefit in refractory female pattern hair loss beyond either drug alone; that higher-than-standard finasteride doses in women outperform 1 mg/day; that dose-based failure thresholds (such as "50% reduction in lesion count at 6 months") predict who benefits from switching versus escalating.

Not established, or requiring individual verification: specific percentage response rates and specific percentage side-effect incidences that different online sources attribute to these drugs vary widely and were not independently verified for this draft; readers should ask their prescriber for the number that applies to their situation rather than relying on any single percentage found online.

Side effects and who tends to tolerate each drug

Deciding what to try next: a failure-pattern framework

Use this table to match the pattern of failure to a reasonable next step. It is a clinical reasoning aid, not a substitute for lab-confirmed diagnosis or a prescriber's judgment, and it does not cover every scenario.

Combining the two drugs

Case reports and small retrospective series describe using finasteride and spironolactone together in women with refractory pattern hair loss who had a partial response to either drug alone, on the reasoning that finasteride lowers the DHT substrate while spironolactone blocks the receptor. This combination has not been tested in a large randomized trial, and the decision to combine, rather than switch or escalate to something outside this drug class (dutasteride, platelet-rich plasma, low-level laser therapy, or hair transplantation for stable diffuse miniaturization), should be individualized with a dermatologist. A combined oral contraceptive containing a low-androgenic progestin is sometimes added at any stage in women not already using hormonal contraception, since raising SHBG lowers free testosterone and can complement either drug.

Special populations

Transgender women. Spironolactone is one of the anti-androgens used in feminizing gender-affirming hormone therapy protocols; readers should consult current endocrinology society guidance and their prescriber for protocol specifics, since guideline detail changes and was not independently re-verified for this draft. Finasteride does not lower circulating testosterone and is not used as a primary anti-androgen in this context, though some clinicians add it specifically to help preserve scalp hair.

Postmenopausal women. Both drugs are used off-label. Spironolactone's blood-pressure-lowering effect can be an advantage in a hypertensive patient but needs monitoring if the patient is already on antihypertensives. Finasteride at standard dosing is a common off-label choice, though supporting evidence is largely observational.

Adolescents. Spironolactone is occasionally used off-label in adolescent girls with polycystic ovarian syndrome-related acne who have not responded to topical or oral antibiotics, always alongside reliable contraception. Finasteride is generally avoided in adolescents and in any premenopausal patient without confirmed reliable contraception, given the teratogenicity concern and limited pediatric safety data.

A practical checklist before starting or switching either drug

• Pregnancy test negative and reliable contraception confirmed and documented (both drugs)
• Baseline labs to rule out non-androgenic causes: free testosterone, DHEA-S, SHBG, TSH, ferritin, CBC
• Baseline blood pressure and renal function before spironolactone
• Baseline PSA in men before finasteride
• Diagnosis confirmed by trichoscopy or biopsy if the clinical picture is atypical
• A documented discussion of the expected trial length (commonly 12 months for hair, 3-6 months for acne in typical practice), the reversal of benefit on stopping, and reproductive risk

When to seek care sooner than a routine follow-up

Sudden or patchy hair loss, hair loss with scalp pain, redness, or scarring, signs of an allergic reaction, chest pain or irregular heartbeat while on spironolactone, or symptoms of hyperkalemia (muscle weakness, palpitations) all warrant contacting a clinician promptly rather than waiting for a scheduled follow-up.